1. Home
  2. INCY

as 07-12-2024 4:00pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Commercial Physical & Biological Resarch

Nasdaq

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Founded: 1991 Country:
United States
United States
Employees: N/A City: WILMINGTON
Market Cap: 12.3B IPO Year: 1993
Target Price: $71.14 AVG Volume (30 days): 3.7M
Analyst Decision: Buy Number of Analysts: 17
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: 3.30 EPS Growth: 129.17
52 Week Low/High: $50.27 - $67.36 Next Earning Date: 07-30-2024
Revenue: $3,767,865,000 Revenue Growth: 8.58%
Revenue Growth (this year): 12.84% Revenue Growth (next year): 10.77%

INCY Daily Stock ML Predictions

Stock Insider Trading Activity of Incyte Corp. (INCY)

Name Ticker Relationship Date Transaction Cost Per Share Shares Total Value Securities Owned After Transaction(s) SEC Form 4
Flannelly Barry P INCY EVP & General Manager US Jun 12 '24 Sell $60.00 19,164 $1,149,840.00 66,377 SEC Form 4
Tray Thomas INCY Principal Accounting Officer Jun 6 '24 Sell $58.91 1,093 $64,388.63 21,634 SEC Form 4
Stein Steven H INCY EVP & Chief Medical Officer Jan 3 '24 Sell $65.51 7,365 $482,481.15 90,218 SEC Form 4
Iyengar Vijay K INCY EVP, GMAPPS Jan 2 '24 Sell $65.00 657 $42,705.00 43,412 SEC Form 4
Tray Thomas INCY Principal Accounting Officer Dec 12 '23 Sell $57.36 210 $12,045.60 24,503 SEC Form 4
Tray Thomas INCY Principal Accounting Officer Dec 12 '23 Sell $62.37 1,067 $66,548.79 23,436 SEC Form 4

Share on Social Networks: